GLPwatch
Wegovy for Opioid use disorder
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for opioid use disorder, and any use for this condition is off-label or investigational. A randomized, double-blind, placebo-controlled clinical trial protocol is studying semaglutide’s efficacy in abstinence from illicit and nonprescribed opioids, but results are not yet available.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Opioid use disorder |
| Approval status | Investigational / off-label |
| Research papers | 4 |
Wegovy is not FDA-approved for opioid use disorder; the research below reflects investigational or off-label study only.
Research on semaglutide for opioid use disorder (4)
- Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
- Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder.
- Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.
- Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.